David Hallal, ElevateBio CEO
ElevateBio snags the year's largest raise with $401M Series D, plus a research partnership with Novo
Just one day after an RNA startup announced a $300 million round, ElevateBio has taken away the record for the industry’s biggest raise of the year, announcing a $401 million Series D round.
Wednesday’s financing means the Waltham, MA-based company has now raised about $1.25 billion over its 5.5-year existence, building what CEO David Hallal called a new type of cell and gene therapy company. It has almost 500 employees and sells a range of services to cell and gene therapy partners, including process development and manufacturing capabilities and even pure-play R&D services.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters